VEGFA and age-related macular degeneration: Over the following decade, structural variants of anti-VEGF were developed and showed similar efficacy to ranibizumab, including bevacizumab, the complete IgG monoclonal antibody that binds all VEGF isoforms (demonstrated in the comparison of age-related macular degeneration treatment trials, CATT) and aflibercept, the decoy receptor of VEGF-A (demonstrated in the VIEW1/2 trials) [15,16,17].